Moderna vaccine reduced viral load and protected against SAR

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

Related Keywords

California , United States , Jocelyn Solis Moreirasep , Jocelyn Solis Moreira , Viral Dynamics , Circulating Viral Variants During , Initial Analysis , Image Credit , Coronavirus Disease Covid 19 , Cars , Ars Cov 2 , Vaccine , Ntibody , Clinical Trial , Coronavirus , Efficacy , Placebo , Research , Espiratory , Evere Acute Respiratory ,